Shanghai Henlius Biotech Inc. (2696.HK) released a profit for full year of RMB827.04 million
The company's bottom line came in at RMB827.04 million, or RMB1.51 per share. This compares with RMB820.47 million, or RMB1.51 per share, last year.
The company's revenue for the period rose 16.5% to RMB6.666 billion from RMB5.724 billion last year.
Shanghai Henlius Biotech Inc. earnings at a glance (GAAP) :
-Earnings: RMB827.04 Mln. vs. RMB820.47 Mln. last year.-EPS: RMB1.51 vs. RMB1.51 last year.-Revenue: RMB6.666 Bln vs. RMB5.724 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.